Peritoneal Cancer

P3, N=468, Recruiting, Hansoh BioMedical R&D Company | Not yet recruiting --> Recruiting

P1, N=27, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed | N=40 --> 27 | Trial completion date: Aug 2026 --> Dec 2025 | Trial primary completion date: Aug 2026 --> Dec 2025

CRS and HIPEC provide 14% 5-year survival for GCA with peritoneal metastases. Complete cytoreduction, especially with PCI < 20, improves outcomes.

P2, N=27, Not yet recruiting, Mayo Clinic

No significant differences in recurrence pattern or survival outcome were observed between CRS with HIPEC and CRS alone. However, distinct recurrence patterns observed in BRCA-mutated patients suggest potential biological differences that may influence treatment outcomes. A trend toward reduced gastrointestinal morbidity in the HIPEC group, potentially reflecting a more subtle, less invasive recurrence pattern. Further research is warranted to elucidate these observations.

P=N/A, N=600, Not yet recruiting, Tongji Hospital

P1/2, N=764, Recruiting, Genmab | N=569 --> 764

P=N/A, N=50, Completed, Rutgers, The State University of New Jersey | Active, not recruiting --> Completed

Additionally, KLK7 overexpression altered cell morphology, upregulated moesin (MSN) and integrin subunits, suggesting cytoskeletal remodeling and matrix interactions. Taken together, these findings suggest that KLK7 is a driver of CRC progression and could serve as a potential prognostic marker for aggressive forms of CRC.

Early trials of FAPI-based radioligand therapies, including &lsqb;¹⁷⁷Lu]FAPI-2286, show promising safety and preliminary efficacy. Based on the current premises, FAPI seems a promising agent for genitourinary oncology, requiring further assessment through prospective studies.

This is the first reported case of recurrent retroperitoneal DDLPS with high TMB achieving pCR to pembrolizumab. High TMB and high TAM density in the tumor microenvironment may be predictive biomarkers for the response to ICIs in DDLPS.

Preoperative CEA elevation >5 in 13 patients showed a median survival of 3 years as compared to 15 patients (53.6 %) with non-elevated CEA with a median survival of 16 years. Preoperative CEA measurement may signal an aberrant tumor biology that indicates patients at high risk of treatment failure for CRS and HIPEC.